Navigation Links
Creabilis Announces Headline Results of its Phase 2b Trial of Topical TrkA Kinase Inhibitor CT327
Date:5/10/2013

.

Creabilis' primary focus is in chronic pruritus, a debilitating symptom of many dermatological diseases with a negative impact on quality of life. Chronic pruritus is an area of significant unmet need, with no medicine currently approved for its treatment.

Creabilis has delivered positive Phase 2b results for CT327 in the treatment of pruritus in psoriasis patients. CT327 is a novel, first-in-class, topically delivered TrkA kinase inhibitor. CT327 was developed using Creabilis' proprietary Low Systemic Exposure (LSE) 'topical-by-design' technology. LSE creates molecules optimized for topical applications. Planning for Phase 3 with CT327 is underway, with a clear route to market and an estimated >$800m in peak annual sales.

Creabilis' pipeline also includes CT340, a potent narrow spectrum kinase inhibitor in development for the topical treatment of neuropathic pain, an area of significant unmet medical need. Like CT327, CT340 was developed using the Company's Low Systemic Exposure (LSE) technology. CT340 is IND-ready and first-in-human studies will commence in 2013.

Creabilis is backed by highly respected life science investors Sofinnova Partners, Neomed and AbbVie Biotech Ventures Inc., and is led by an experienced Management team, with over 100 years of combined R&D experience in pharma and biotech, and over 20 drug approvals.

For further information please contact:

Creabilis
Eliot Forster
info@creabilis-sa.com
Creabilis SA
15 rue Edward Steichen
L-2540 Luxembourg
                   
Citigate Dewe Rogerson
Chris Gardner or Nina Enegren
Tel: +44(0)20-7282-1050
E-mail: nin
'/>"/>

SOURCE Creabilis SA
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Creabilis Awarded Prestigious European Commission FP7 Grant to Further Develop its LSE Topical-by-Design Technology
2. Omeros Announces $16.2 Million Registered Direct Offering of Common Stock
3. Allscripts announces first quarter 2013 results
4. The MED Group Announces New Agreement with CareCentrix Effective May 1, 2013
5. ASSA ABLOY Door Group Announces RF Shielding Openings
6. APHY announces new store openings as part of major expansion
7. NxStage Announces Second Quarter 2013 Investor Conference Schedule
8. Pro-Dex, Inc. Announces Fiscal 2013 Third Quarter Financial Results Conference Call and Webcast
9. Parametrics Medical, LLC Announces the Release of Their Coll-e-Strong Line of Soft Tissue Allografts
10. Sequenom Announces Participation At The Bank Of America Merrill Lynch Health Care Conference
11. GW Pharmaceuticals plc Announces the Closing of its Initial Public Offering on the Nasdaq Global Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Edwards Lifesciences Corporation (NYSE: EW ), the ... monitoring, today announced that Robert A. Ingram has ... is an ardent champion for innovation in the lifesciences industry, ... on Edwards, board as we pursue our focused innovation strategy," ... "Bob has provided a valuable perspective to our board, drawing ...
(Date:7/30/2015)...  ResMed Inc. (NYSE: RMD ) today announced ... for the quarter was $453.1 million, a 9 percent ... (a 17 percent increase on a constant currency basis). ... ended June 30, 2014.  Diluted earnings per share for ... June 30, 2014.  The results for ...
(Date:7/30/2015)... July 30, 2015  Unichem Pharmaceuticals ( USA ... of Hydrochlorothiazide tablets 25 mg 1000-count bottle to the ... precautionary measure due to the identification of a Clopidogrel ... The risk associated with mistakenly taking a ... increased probability of experiencing Clopidogrel,s side effects which include ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2
... ... at ADA 2008, ... today announced data showing that the use of mealtime,SYMLIN(R) (pramlintide acetate) ... achieving diabetes treatment goals of,improved glucose control without weight gain or ...
... Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today ... with AZ-002 (Staccato(R),alprazolam) in patients with panic disorder. ... which were the effect of AZ-002 on the ... of AZ-002 on the duration of a,doxapram-induced panic ...
Cached Medicine Technology:Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 2Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 3Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 4Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 5Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder 2Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder 3Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder 4
(Date:7/31/2015)... WA (PRWEB) , ... July 31, 2015 , ... BioViva ... transforming the way we treat aging diseases. , BioViva announces it has begun ... treat patients with Alzheimer’s Disease (AD) and find a cure. MaxLife will grant 100% ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... Northern District of Ohio, Western Division (Case No. 3:15-cv-00397) involving the Implanon® ... women experienced spontaneous migration of their Implanon® implants, inability to locate the implants, ...
(Date:7/31/2015)... Calgary, AB (PRWEB) , ... July 31, 2015 , ... ... changes. "When patients don't experience angina until a heart rate of 150 beats versus ... Fit Clinic in Calgary. "We are able to give life back to patients with ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... RenovoCath,™ a novel catheter that was developed for targeted delivery of fluids to ... now being treated at Florida Hospital Tampa with the device that provides direct, ...
(Date:7/31/2015)... ... July 31, 2015 , ... Patients with higher levels ... a study published today in Nature Communications and led by researchers from the Icahn ... that variations in the gene RTN1 led to greater production of the related RNT1 ...
Breaking Medicine News(10 mins):Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 3Health News:Heart Fit Clinic Helps Patient Increase Fitness Level with External Counterpulsation 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 3
... Hometown Huddle Day and Air ... ... &,Human Services (HHS), the Ad Council and the National Football League (NFL),will ... to combat childhood obesity by encouraging physical,activity among children. The new ads, ...
... 9 Friends of Morongo fire chief,Phil Kelleher are ... raise,funds for him and his family. Widely known and ... lateral sclerosis (ALS),also known as Lou Gehrig,s disease. ... cells in the brain and spinal cord resulting in ...
... $260,000 for ORBIS Children,s Eye Care Project ... ... Lehka Pendyala, ages 8 and 6,will launch a kid-inspired and kid-driven campaign ... Their,ultimate goal is to raise $260,000 for a specialized pediatric eye care,unit ...
... COLUMBUS, Ohio -- Nurses and physicians at Nationwide Childrens Hospital ... endure the extreme pain of dressing changes and wound care. ... music, Nationwide Childrens Hospital Burn Center is now using virtual ... patients burn wounds. , Its long been known ...
... unveiled at Healthcare Communications Forum, November 5, ... ... today announced,seven finalists for the 2007 Insight Award for Customer Advocacy in,Healthcare. ... of health care services need,to make fully informed choices and successful purchase ...
... Pharmaceuticals,Inc. (Nasdaq: NPSP ) announced today that ... AstraZeneca to discover and develop drugs targeting,metabotropic glutamate ... million to acquire NPS,s assets related to the ... NPS intends to use the,proceeds to support further ...
Cached Medicine News:Health News:Video and Photo: U.S. Department of Health & Human Services and Ad Council Join NFL to Combat Childhood Obesity 2Health News:Video and Photo: U.S. Department of Health & Human Services and Ad Council Join NFL to Combat Childhood Obesity 3Health News:Video and Photo: U.S. Department of Health & Human Services and Ad Council Join NFL to Combat Childhood Obesity 4Health News:Fundraiser Announced for Morongo Fire Chief; Veteran Firefighter Diagnosed With ALS 2Health News:Fundraiser Announced for Morongo Fire Chief; Veteran Firefighter Diagnosed With ALS 3Health News:Elementary School Students to Launch 'Kids for Sight' Campaign, to Inspire Other Kids to Pay it Forward 2Health News:Elementary School Students to Launch 'Kids for Sight' Campaign, to Inspire Other Kids to Pay it Forward 3Health News:Virtual game helps children escape realities of burn unit 2Health News:NPS Sells Assets Related to mGluR Collaboration to AstraZeneca for $30 Million to Support Late-Stage Product Development 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: